摘要
目的探讨MAT1基因及其蛋白在乳腺癌中的表达及意义。方法选择60例乳腺癌标本和20例正常乳腺标本,采用原位杂交和免疫组化SP法分别检测乳腺癌组织中MAT1 mRNA及MAT1蛋白的表达水平,分析其与乳腺癌临床病理学特征之间的关系。结果 38例(63.33%)MAT1 mRNA阳性,32例(53.33%)MAT1蛋白阳性,在乳腺癌组织中阳性表达率及表达强度显著高于正常乳腺癌组织(P<0.05)。不同临床分期、组织病理学分级及有无淋巴结转移MAT1 mRNA阳性率和MAT1蛋白阳性率比较,差异均有统计学意义(P<0.05),MAT1 mRNA和MAT1蛋白表达分别与临床分期正相关(P<0.05)。结论 MAT1 mRNA及MAT1蛋白在乳腺癌组织中高表达,表达水平与临床分期、组织病理学分级和淋巴结转移密切相关,可作为判断乳腺癌的进展、转移的参考指标及治疗的新靶点。
Objective To investigate the expression of molecular switch MAT1 gene and its protein in breast cancer. Methods 60 cases of breast cancer specimens and 20 normal breast specimens, using in situ hybridization and immunohistochemical SP method was used to detect breast cancer tissues MAT1 MAT1 mRNA and protein levels, analyze its relationship with clinicopathological features of breast cancer relationships, Results 38 cases(63.33%) of MAT1 mRNA-positive, 32 cases(53.33%) of MATI protein, MATI mRNA-positive and MATI protein positive expression rates in breast cancer were significantly higher than normal breast tissue (P〈0.05). The differences of MAT1 mRNA-positive and MAT1 protein positive rates among different clinical stages, different histological grade and lymph node metastasis were statistically significant (P〈0.05), MATI mRNA and protein expression of MAT1 were positively correlated with clinical stage (P〈0.05). Conclusion MAT1 mRNA and MAT1 protein is highly expressed in breast cancer tissues, expression levels with clinical stage, histological grade and lymph node metastasis, could be used as breast cancer progression and metastasis reference index and a new therapeutic target.
出处
《中国医药指南》
2013年第34期1-3,共3页
Guide of China Medicine
基金
福建省自然科学基金项目(2006J0384)